The abstract is read at the publisher; the summary is JClub's.
Neddylated ABTB1 suppresses Th17 cell differentiation by acting as an E3 ubiquitin ligase that promotes STAT3 polyubiquitination and degradation.
- Why it matters: Th17 differentiation and STAT3 activation drive autoimmune inflammation, but the upstream regulators controlling STAT3 ubiquitination in this context were unclear.
- What they did: The study showed ABTB1 deficiency enhances Th17 differentiation and worsens DSS-induced colitis, alongside reduced STAT3 polyubiquitination with increased STAT3 total levels and phosphorylation. It also demonstrated neddylated ABTB1 mediates K27-, K33-, and K48-linked polyubiquitination of STAT3, targeting it to the ubiquitin-proteasome pathway.
- The result: By inhibiting excessive STAT3 activation, ABTB1 suppresses Th17 differentiation and mitigates autoimmune inflammation, suggesting ABTB1 as a potential therapeutic target for IBD and other autoimmune disorders.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.